(NASDAQ: BTAI) Bioxcel Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.75%.
Bioxcel Therapeutics's earnings in 2025 is -$40,062,000.On average, 2 Wall Street analysts forecast BTAI's earnings for 2025 to be -$52,081,996, with the lowest BTAI earnings forecast at -$55,533,942, and the highest BTAI earnings forecast at -$48,630,049.
In 2026, BTAI is forecast to generate -$42,513,443 in earnings, with the lowest earnings forecast at -$71,885,266 and the highest earnings forecast at -$13,141,620.